We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Onyx Pharmaceuticals and the FDA have agreed on a special protocol assessment (SPA) for a Phase III trial of the company’s multiple myeloma treatment candidate carfilzomib.